Macrophage activation syndrome at the onset of glucocorticoid-resistant systemic lupus erythematosus: a case report

1. AGGARWAL R, RINGOLD S, KHANNA D, NEOGI T, JOHNSON SR, MILLER A, et al. Distinctions between diagnostic and classification criteria? Arthritis care & research. 2015; 67(7):891-7.10.1002/acr.22583Search in Google Scholar

2. LUIJTEN RK, FRITSCH-STORK RD, BIJLSMA JW, DERKSEN RH. The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. Autoimmunity reviews. 2013; 12(5):617-28.10.1016/j.autrev.2012.12.001Open DOISearch in Google Scholar

3. PETRI M, ORBAI AM, ALARCON GS, GORDON C, MERRILL JT, FORTIN PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and rheumatism. 2012; 64(8):2677-86.10.1002/art.34473Search in Google Scholar

4. BARCELLINI W. Current treatment strategies in autoimmune hemolytic disorders. Expert review of hematology. 2015; 8(5):681-91.10.1586/17474086.2015.1073105Search in Google Scholar

5. ADAMS PC, BARTON JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. Journal of hepatology. 2011; 55(2):453-8.10.1016/j.jhep.2011.02.010Search in Google Scholar

6. KIM SE, KIM UJ, JANG MO, KANG SJ, JANG HC, JUNG SI, et al. Diagnostic use of serum ferritin levels to differentiate infectious and noninfectious diseases in patients with fever of unknown origin. Disease markers. 2013; 34(3):211-8.10.1155/2013/915389Search in Google Scholar

7. GAVAND PE, SERIO I, ARNAUD L, COSTEDOAT-CHALUMEAU N, CARVELLI J, DOSSIER A, et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. Autoimmunity reviews. 2017; 16(7):743-9.10.1016/j.autrev.2017.05.010Open DOISearch in Google Scholar

8. RIVIERE S, GALICIER L, COPPO P, MARZAC C, AUMONT C, LAMBOTTE O, et al. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. The American journal of medicine. 2014; 127(11):1118-25.10.1016/j.amjmed.2014.04.034Search in Google Scholar

9. TAKAHASHI H, TSUBOI H, KURATA I, TAKAHASHI H, INOUE S, EBE H, et al. Predictors of the response to treatment in acute lupus hemophagocytic syndrome. Lupus. 2015; 24(7):659-68.10.1177/0961203314559086Search in Google Scholar

10. INGAWALE DK, MANDLIK SK, PATEL SS. An emphasis on molecular mechanisms of anti-inflammatory effects and glucocorticoid resistance. Journal of complementary & integrative medicine. 2015; 12(1):1-13.10.1515/jcim-2014-0051Search in Google Scholar

11. ZHANG B, SHI Y, LEI TC. Detection of active P-glycoprotein in systemic lupus erythematosus patients with poor disease control. Experimental and therapeutic medicine. 2012; 4(4):705-10.10.3892/etm.2012.667Search in Google Scholar

12. DEJAGER L, VANDEVYVER S, PETTA I, LIBERT C. Dominance of the strongest: inflammatory cytokines versus glucocorticoids. Cytokine & growth factor reviews. 2014; 25(1):21-33.10.1016/j.cytogfr.2013.12.006Search in Google Scholar